Acer Therapeutics Inc.
- Tickers
- None listed
- Headquarters
- Not recorded
- SEC CIK
- 0001069308
- Website
- Not recorded
Closing prices
This company has no stock ticker on record, so there are no prices to show.
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| ACER-002 | Vascular Ehlers-Danlos Syndrome | Phase 3 | None scheduled | 1 |
FDA-approved applications
| Application | Brand names | Active ingredients | First approved | Status |
|---|---|---|---|---|
| NDA 214860 | OLPRUVA | SODIUM PHENYLBUTYRATE | Prescription |
Open in the approved-drug database for Acer Therapeutics Inc.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 371,790 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −14,731,267 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 1,522,161 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | 13,249,728 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 594,659 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 61,747,027 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | −47,744,962 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 24,463,726 shares | At 8 Nov 2023 FY2023 Q3 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 371,790 USD | 10-Q filed 20 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2021 to 31 Dec 2021 FY2022 | 1,260,000 USD | 10-K filed 27 Mar 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2021 to 31 Mar 2021 FY2022 Q1 | 900,000 USD | 10-Q filed 16 May 2022 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2020 to 31 Dec 2020 FY2021 | 0 USD | 10-K filed 2 Mar 2022 on sec.gov (opens in a new tab)Filed |
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Acer Therapeutics Inc. on Insider TradesLast 90 days of Form 4 filings, from 15 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.